Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F. Humbert O, et al. Among authors: coutant c. Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33. doi: 10.1007/s00259-014-2739-1. Epub 2014 Mar 20. Eur J Nucl Med Mol Imaging. 2014. PMID: 24647576
Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.
Frati A, Chereau E, Coutant C, Bezu C, Antoine M, Chopier J, Daraï E, Uzan S, Gligorov J, Rouzier R. Frati A, et al. Among authors: coutant c. Breast Cancer Res Treat. 2012 Apr;132(2):601-7. doi: 10.1007/s10549-011-1897-0. Epub 2011 Dec 9. Breast Cancer Res Treat. 2012. PMID: 22160638
¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F. Cochet A, et al. Among authors: coutant c. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37. doi: 10.1007/s00259-013-2595-4. Epub 2013 Nov 7. Eur J Nucl Med Mol Imaging. 2014. PMID: 24196916
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, Desmoulins I, Toubeau M, Dygai-Cochet I, Coutant C, Fumoleau P, Brunotte F. Humbert O, et al. Among authors: coutant c. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27. doi: 10.1007/s00259-013-2616-3. Epub 2013 Nov 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 24258007
Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene.
Degrolard-Courcet E, Sokolowska J, Padeano MM, Guiu S, Bronner M, Chery C, Coron F, Lepage C, Chapusot C, Loustalot C, Jouve JL, Hatem C, Ferrant E, Martin L, Coutant C, Baurand A, Couillault G, Delignette A, El Chehadeh S, Lizard S, Arnould L, Fumoleau P, Callier P, Mugneret F, Philippe C, Frebourg T, Jonveaux P, Faivre L. Degrolard-Courcet E, et al. Among authors: coutant c. Eur J Hum Genet. 2014 Aug;22(8):979-87. doi: 10.1038/ejhg.2013.278. Epub 2013 Dec 4. Eur J Hum Genet. 2014. PMID: 24301060 Free PMC article. Review.
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, Brunotte F. Humbert O, et al. Among authors: coutant c. Clin Cancer Res. 2015 Dec 15;21(24):5460-8. doi: 10.1158/1078-0432.CCR-15-0384. Epub 2015 Jun 30. Clin Cancer Res. 2015. PMID: 26130460
270 results